Cargando…

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features

RNA binding motif 5 (RBM5) is a tumor suppressor gene that regulates cell proliferation, differentiation and apoptosis through pre-mRNA splicing of related genes. This study aimed to detect RBM5 and KRAS expression in pancreatic ductal adenocarcinoma and their association with clinicopathological fe...

Descripción completa

Detalles Bibliográficos
Autores principales:	PENG, JIE, VALESHABAD, ALI KORD, LI, QINGFU, WANG, YUAN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576315/ https://www.ncbi.nlm.nih.gov/pubmed/23425895 http://dx.doi.org/10.3892/ol.2012.1080

Ejemplares similares

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
por: Zhu, Liang, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

The effects of CYP24A1 on clinicopathological features and the prognosis of pancreatic ductal adenocarcinoma
por: Gao, Wei, et al.
Publicado: (2020)

Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
por: Park, Sejun, et al.
Publicado: (2023)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma
por: Matsushita, Katsunori, et al.
Publicado: (2021)

Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma
por: Avila, Jacqueline L., et al.
Publicado: (2012)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues
por: Liang, Hong, et al.
Publicado: (2012)

Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival
por: Pergolini, Ilaria, et al.
Publicado: (2017)

Perineural Invasion and TAMs in Pancreatic Ductal Adenocarcinomas: Review of the Original Pathology Reports Using Immunohistochemical Enhancement and Relationships with Clinicopathological Features
por: Zeng, Linjuan, et al.
Publicado: (2014)

Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma
por: Jamiyan, Tsengelmaa, et al.
Publicado: (2020)

Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes
por: Badowska-Kozakiewicz, Anna, et al.
Publicado: (2022)

Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma
por: Vay, Christian, et al.
Publicado: (2022)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

New Morphological Features for Grading Pancreatic Ductal Adenocarcinomas
por: Song, Jae-Won, et al.
Publicado: (2013)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

RBM6-RBM5 transcription-induced chimeras are differentially expressed in tumours
por: Wang, Ke, et al.
Publicado: (2007)

A feasible CT feature to differentiate focal‐type autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: He, Chaobin, et al.
Publicado: (2019)

Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma
por: Ju, Huai-Qiang, et al.
Publicado: (2017)

Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis
por: Wang, Jin-Dao, et al.
Publicado: (2016)

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence
por: Amintas, Samuel, et al.
Publicado: (2022)

Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma
por: Kong, Yao, et al.
Publicado: (2023)

Papillon-Lefèvre Syndrome: A Series of Six Cases in the Same Family
por: Kord Valeshabad, Ali, et al.
Publicado: (2012)

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
por: Ni, Qian‐Zhi, et al.
Publicado: (2022)

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
por: Topham, James T., et al.
Publicado: (2022)

The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis
por: Guo, Chuangen, et al.
Publicado: (2018)

Differentiation of pancreatic ductal adenocarcinoma and chronic pancreatitis using graph neural networks on histopathology and collagen fiber features
por: Li, Bin, et al.
Publicado: (2022)

Overexpression of RBM5 induces autophagy in human lung adenocarcinoma cells
por: Su, Zhenzhong, et al.
Publicado: (2016)

Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: Caba, Octavio, et al.
Publicado: (2023)

CXCR4-A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis
por: Krieg, Andreas, et al.
Publicado: (2015)

Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2021)

Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma
por: Wang, Yuqiong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_njnvnocl7q42hfo91ljkbrnok8